The nasal spray is indicated to treat known or suspected opioid overdose in adults and paediatric patients aged 12 years and above. Credit: Alliance Images via Shutterstock.com.

The US Food and Drug Administration (FDA) for 鈥檚 Opvee (nalmefene) nasal spray to reverse opioid overdose.

Opvee is indicated for the emergency treatment of known or suspected opioid overdose in adults and paediatric patients aged 12 years and above.

Go deeper with GlobalData

  • ReportsLogo

  • ReportsLogo

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

It comprises the opioid receptor antagonist nalmefene, which offers quick onset and long-duration reversal of the opioid-induced respiratory depression that is said to be the main cause of opioid overdose injury and death.

Opvee was added to Indivior鈥檚 portfolio through the purchase of in March 2023.

Indivior CEO Mark Crossley said: 鈥淥pvee鈥檚 FDA approval represents a significant achievement in the development of new treatment options to address today鈥檚 era of opioid overdoses that are driven by powerful synthetic opioids such as fentanyl.

鈥淥pvee is an emergency treatment for the fast reversal of respiratory depression triggered by natural or synthetic opioids, including fentanyl, and we are committed to making this novel rescue medication widely available to those who need it most to help save lives.鈥�

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The regulatory approval was based on the findings obtained from a pharmacodynamic study, which was conducted on 61 opioid-experienced, non-dependent participants.

The trial was designed to determine the pharmacodynamics of nalmefene when given intranasally against intranasal naloxone to healthy subjects under steady-state opioid agonism.

Findings showed that the time taken to the onset of the reversal of respiratory depression was between 2.5 and five minutes. Complete recovery of the respiratory drive was demonstrated as early as five minutes after administrating Opvee.

Indivior will begin offering Opvee in the market in the fourth quarter of 2023.